アブストラクト
Japanese
| Title | 再発小細胞肺がんに対するアムルビシン療法における重篤な好中球減少と無増悪生存期間の関連性 |
|---|---|
| Subtitle | ノート |
| Authors | 石田翔1, 妹尾啓司1, 宮嵜純治1, 中井將人1, 水上皓喜1, 白木政博1, 阪田安彦2, 渡邊篤1 |
| Authors (kana) | |
| Organization | 1地方独立行政法人 広島市立病院機構 広島市立広島市民病院 薬剤部, 2地方独立行政法人 広島市立病院機構 広島市立北部医療センター安佐市民病院 薬剤部 |
| Journal | 医療薬学 |
| Volume | 49 |
| Number | 10 |
| Page | 374-384 |
| Year/Month | 2023 / 10 |
| Article | 報告 |
| Publisher | 日本医療薬学会 |
| Abstract | 「緒言」小細胞肺がん (small cell lung cancer : SCLC) は, 肺がん患者の10〜15%を占める組織型であり, SCLCの治療戦略を考えるうえでは限局型 (limited disease : LD) と進展型 (extensive disease : ED) に大別する分類が汎用されている. SCLCは, 抗がん剤への感受性が高いという特性を有しているため, LDでは術後補助化学療法や化学放射線療法として, EDでは治療の主体として薬物療法が選択され, プラチナ製剤やトポイソメラーゼ阻害薬, また近年では免疫チェックポイント阻害薬 (immune checkpoint inhibitor : ICI) が主に用いられる. しかし, LD, EDのいずれの病期においても, 多くのSCLC患者は, 初回治療で一旦は奏効が得られるが, 短期間のうちに再発, 増悪を来たし, 全身状態が維持されていれば二次治療が施行されるが, 初回治療と比較して薬物療法への反応が悪く, 予後不良である. |
| Practice | 薬学 |
| Keywords | amrubicin, recurrent small cell lung cancer, progression-free survival, neutropenia, febrile neutropenia, chemotherapy |
English
| Title | Association between Severe Neutropenia Induced by Amrubicin Therapy and Progression-free Survival in Recurrent Small Cell Lung Cancer |
|---|---|
| Subtitle | Notes |
| Authors | Sho Ishida1, Keiji Seo1, Junji Miyazaki1, Masato Nakai1, Kouki Mizukami1, Masahiro Shiraki1, Yasuhiko Sakata2, Atsushi Watanabe1 |
| Authors (kana) | |
| Organization | 1Department of Pharmacy, Hiroshima City Hiroshima Citizens Hospital, 2Department of Pharmacy, Hiroshima City North Medical Center Asa Citizens Hospital |
| Journal | Japanese Journal of Pharmaceutical Health Care and Sciences |
| Volume | 49 |
| Number | 10 |
| Page | 374-384 |
| Year/Month | 2023 / 10 |
| Article | Report |
| Publisher | Japanese Society of Pharmaceutical Health Care and Sciences |
| Abstract | Amrubicin (AMR) is recommended for the treatment of recurrent small cell lung cancer (SCLC) in Japan, but neutropenia is frequently observed as an adverse effect. However, the relationship between severe neutropenia caused by chemotherapy and treatment response remains controversial in AMR. We examined the association between severe neutropenia induced by AMR and progression-free survival (PFS) in recurrent SCLC. The study included 115 patients who started AMR at Hiroshima Citizens Hospital between July 2011 and June 2021. We defined Grade >- 3 as severe neutropenia, retrospectively investigated patient background, the cumulative number of courses with severe neutropenia among all courses (incidence rate of severe neutropenia), and PFS. Cox proportional hazards regression analysis revealed that the performance status of the Eastern Cooperative Oncology Group (hazard ratio (HR) = 2.503, P < 0.001), previous therapy (topoisomerase inhibitors) (HR = 1.758, P = 0.041), stage at diagnosis (HR = 1.746, P = 0.024), and incidence rate of severe neutropenia (HR = 1.636, P = 0.025) were factors significantly related to PFS. The patients were classified into the high and low groups based on the incidence rate of severe neutropenia, and we also extracted 27 cases each from the high and low groups using propensity score matching. A comparison of PFS in both groups showed that the high group had a significantly shorter PFS (P = 0.019). Therefore, our findings suggest that management of neutropenia during AMR treatment in recurrent SCLC may contribute to prolonged PFS. |
| Practice | Pharmaceutical sciences |
| Keywords | amrubicin, recurrent small cell lung cancer, progression-free survival, neutropenia, febrile neutropenia, chemotherapy |
- 全文ダウンロード： 従量制、基本料金制の方共に770円(税込) です。
参考文献
- 1) Toyoda Y, Nakayama T, Ioka A, Tsukuma H, Trends in lung cancer incidence by histological type in Osaka, Japan, Jpn J Clin Oncol, 2008, 38, 534-539.
- 2) 日本肺癌学会, "肺癌診療ガイドライン", 2022年版, 金原出版, 東京, 2022, pp257-295.
- 3) Byers LA, Rudin CM, Small cell lung cancer: where do we go from here?, Cancer, 2015, 121, 664-672.
- 4) 村上晴, 再発小細胞肺癌(sensitive relapse and refractory relapse), 肺癌, 2015, 55, 843-846.
- 5) Inoue A, Sugawara S, Yamazaki K, Maemondo M, Suzuki T, Gomi K, Takanashi S, Inoue C, Inage M, Yokouchi H, Watanabe H, Tsukamoto T, Saijo Y, Ishimoto O, Hommura F, Nukiwa T, Randomized phase II trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer: North Japan Lung Cancer Study Group Trial 0402, J Clin Oncol, 2008, 26, 5401-5406.
残りの16件を表示する
- 6) Murakami H, Yamamoto N, Shibata T, Takeda K, Ichinose Y, Ohe Y, Yamamoto N, Takeda Y, Kudoh S, Atagi S, Satouchi M, Kiura K, Nogami N, Endo M, Watanabe H, Tamura T, A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901), Lung Cancer, 2014, 84, 67-72.
- 7) DiBonaventura MD, Shah-Manek B, Higginbottom K, Penrod JR, Yuan Y, Adherence to recommended clinical guidelines in extensive disease small-cell lung cancer across the US, Europe, and Japan, Ther Clin Risk Manag, 2019, 15, 355-366.
- 8) Kishida Y, Kawahara M, Teramukai S, Kubota K, Komuta K, Minato K, Mio T, Fujita Y, Yonei T, Nakano K, Tsuboi M, Shibata K, Atagi S, Kawaguchi T, Furuse K, Fukushima M, Chemotherapy-induced neutropenia as a prognostic factor in advanced non-small-cell lung cancer: results from Japan Multinational Trial Organization LC00-03, Br J Cancer, 2009, 101, 1537-1542.
- 9) Kosaka T, Shinojima T, Morita S, Oya M, Prognostic significance of grade 3/4 neutropenia in Japanese prostate cancer patients treated with cabazitaxel, Cancer Sci, 2018, 109, 1570-1575.
- 10) Singh S, Parulekar W, Murray N, Feld R, Evans WK, Tu D, Shepherd FA, Influence of sex on toxicity and treatment outcome in small-cell lung cancer, J Clin Oncol, 2005, 23, 850-856.
- 11) Dotsu Y, Yamaguchi H, Fukuda M, Suyama T, Honda N, Umeyama Y, Taniguchi H, Gyotoku H, Takemoto S, Tagawa R, Ogata R, Tomono H, Shimada M, Senju H, Nakatomi K, Nagashima S, Soda H, Ikeda H, Ashizawa K, Mukae H, Real-World Incidence of Febrile Neutropenia among Patients Treated with Single-Agent Amrubicin: Necessity of the Primary Prophylactic Administration of Granulocyte Colony-Stimulating Factor, J Clin Med, 2021, 10, 4221. doi: 10.3390/jcm10184221.
- 12) Igawa S, Ono T, Kasajima M, Manabe H, Fukui T, Mitsufuji H, Yokoba M, Kubota M, Katagiri M, Sasaki J, Naoki K, Impact of Amrubicin Monotherapy as Second-Line Chemotherapy on Outcomes in Elderly Patients with Relapsed Extensive-Disease Small-Cell Lung Cancer, Cancer Manag Res, 2020, 12, 4911-4921.
- 13) Uda S, Yamada T, Yoshimura A, Goto Y, Yoshimine K, Nakamura Y, Shiotsu S, Yokoi T, Tamiya N, Kimura H, Chihara Y, Umeda Y, Izumi M, Takeda T, Yamada T, Hibino M, Hiranuma O, Ito K, Okada A, Osugi S, Takemura Y, Ishii H, Chibana K, Hasegawa I, Morimoto Y, Iwasaku M, Tokuda S, Takayama K, Clinical impact of amrubicin monotherapy in patients with relapsed small cell lung cancer: a multicenter retrospective study, Transl Lung Cancer Res, 2022, 11, 1847-1857.
- 14) Kanda Y, Investigation of the freely available easy-to-use software 'EZR' for medical statistics, Bone Marrow Transplant, 2013, 48, 452-458.
- 15) Rocconi RP, Matthews KS, Kemper MK, Hoskins KE, Barnes MN, Chemotherapy-related myelosuppression as a marker of survival in epithelial ovarian cancer patients, Gynecol Oncol, 2008, 108, 336-341.
- 16) Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D, Tsuda H, Sugiyama T, Kodama S, Kimura E, Ochiai K, Noda K, Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial, Lancet, 2009, 374, 1331-1338.
- 17) Hata A, Katakami N, Fujita S, Kaji R, Nanjo S, Otsuka K, Kida Y, Higashi Y, Tachikawa R, Hayashi M, Nishimura T, Tomii K, Amrubicin at a lower-dose with routine prophylactic use of granulocyte-colony stimulating factor for relapsed small-cell lung cancer, Lung Cancer, 2011, 72, 224-228.
- 18) Shimokawa T, Shibuya M, Kitamura K, Hosomi Y, Hibino S, Ota T, Iguchi M, Okamura T, Gemma A, Retrospective analysis of efficacy and safety of amrubicin in refractory and relapsed small-cell lung cancer, Int J Clin Oncol, 2009, 14, 63-69.
- 19) Sato Y, Iihara H, Kinomura M, Hirose C, Fujii H, Endo J, Yanase K, Kaito D, Sasaki Y, Gomyo T, Sakai C, Iwai M, Tsuboi Y, Ishihara T, Kobayashi R, Ohno Y, Suzuki A, Primary Prophylaxis of Febrile Neutropenia With Pegfilgrastim in Small-cell Lung Cancer Patients Receiving Amrubicin as Second-line Therapy, Anticancer Res, 2021, 41, 1615-1620.
- 20) 日本癌治療学会, "G-CSF適正使用ガイドライン", 2022年10月改訂第2版, 金原出版, 東京, 2022, pp36-39.
- 21) Imai H, Nagai Y, Minemura H, Tsuda T, Yamada Y, Wasamoto S, Kishikawa T, Shiono A, Shiihara J, Yamaguchi O, Mouri A, Kaira K, Kanazawa K, Taniguchi H, Minato K, Kagamu H, Efficacy and safety of amrubicin monotherapy after atezolizumab plus carboplatin and etoposide in patients with relapsed small-cell lung cancer, Invest New Drugs, 2022, 40, 1066-1079.
